Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2013-01-11653,2013,Einarson 2013 J Med Econ,Cost-Saving,Long acting paliperidone palmitate VERSUS Long acting risperidone microspheres IN Specific disease- chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland.,23844621,Specific disease- chronic schizophrenia; Age- Adult; Gender- Both; Country- Finland.,Long acting paliperidone palmitate,Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.,Long acting risperidone microspheres,SE
2013-01-10857,2013,Ridderstrale 2013 J Med Econ,32000,Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Unknown; Gender- Both; Country- Norway; Other- Insulin naïve.,23384160,Specific disease- type 2 diabetes; Age- Unknown; Gender- Both; Country- Norway; Other- Insulin naïve.,Insulin determir,"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.",Neutral protamine hagedorn (NPH),NE
2013-01-10857,2013,Ridderstrale 2013 J Med Econ,33000,Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Denmark; Other- Insulin naïve.,23384160,Specific disease- type 2 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Insulin naïve.,Insulin determir,"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.",Neutral protamine hagedorn (NPH),NE
2013-01-10857,2013,Ridderstrale 2013 J Med Econ,36000,Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Adult; Gender- Both; Country- Sweden; Other- Insulin naïve.,23384160,Specific disease- type 2 diabetes; Age- Adult; Gender- Both; Country- Sweden; Other- Insulin naïve.,Insulin determir,"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.",Neutral protamine hagedorn (NPH),NE
2013-01-10857,2013,Ridderstrale 2013 J Med Econ,41000,Insulin determir VERSUS Neutral protamine hagedorn (NPH) IN Specific disease- Type 2 diabetes mellitus; Age- Unknown; Gender- Both; Country- Finland; Other- Insulin naïve.,23384160,Specific disease- type 2 diabetes; Age- Unknown; Gender- Both; Country- Finland; Other- Insulin naïve.,Insulin determir,"Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.",Neutral protamine hagedorn (NPH),NE
2013-01-10721,2013,Tuominen 2013 Int J Technol Assess Health Care,Cost-Saving,Short waiting time with a maximum period of 3 months for total hip replacement surgery VERSUS Nonfixed waiting time with surgery performed according to the hospital's routine procedure IN Specific disease- Osteoarthritis of the hip; Age-; Gender- Both; Country- Finland.,23298468,Specific disease- Osteoarthritis of the hip; Age-; Gender- Both; Country- Finland.,Short waiting time with a maximum period of 3 months for total hip replacement surgery,Cost-utility of waiting time in total joint replacements: a randomized clinical trial.,Nonfixed waiting time with surgery performed according to the hospital's routine procedure,SE
2013-01-10721,2013,Tuominen 2013 Int J Technol Assess Health Care,Dominated,Short waiting time with a maximum period of 3 months for total knee replacement surgery VERSUS Nonfixed waiting time with surgery performed according to the hospital's routine procedure IN Specific disease- Osteoarthiritis of the knee; Age-; Gender- Both; Country- Finland.,23298468,Specific disease- Osteoarthiritis of the knee; Age-; Gender- Both; Country- Finland.,Short waiting time with a maximum period of 3 months for total knee replacement surgery,Cost-utility of waiting time in total joint replacements: a randomized clinical trial.,Nonfixed waiting time with surgery performed according to the hospital's routine procedure,NW
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,100000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- acute kidney injury (AKI) and chronic renal disease before, but no need for chronic renal replacement therapy afterward (RRT); Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",23184040,"Specific disease- acute kidney injury (AKI) and chronic renal disease before, but no need for chronic renal replacement therapy afterward (RRT); Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,17000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- acute kidney injury (AKI) and no chronic renal disease before or after hospitalization; Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",23184040,"Specific disease- acute kidney injury (AKI) and no chronic renal disease before or after hospitalization; Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,18000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- Hospital survivors with acute kidney injury (AKI) and no chronic renal disease before, but need for chronic renal replacement therapy afterward (RRT); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",23184040,"Specific disease- Hospital survivors with acute kidney injury (AKI) and no chronic renal disease before, but need for chronic renal replacement therapy afterward (RRT); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 49-72 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,20000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- acute kidney injury (AKI); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- 49-72 years.",23184040,"Specific disease- acute kidney injury (AKI); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- 49-72 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,400000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- acute kidney injury (AKI); Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 50-65 years.",23184040,"Specific disease- acute kidney injury (AKI); Age- 41 to 64 years, >=65 years; Gender- Not Specified; Country- Finland; Other- 50-65 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2013-01-10084,2013,Laukkanen 2013 Intensive Care Med,81000,"Acute renal replacement therapy (RRT) VERSUS None IN Specific disease- acute kidney injury (AKI), chronic renal disease before, and need; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- 49-72 years.",23184040,"Specific disease- acute kidney injury (AKI), chronic renal disease before, and need; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- 49-72 years.",Acute renal replacement therapy (RRT),Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.,None,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,10000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Croatia",22843446,Patients hospitalized for acute coronary event or cardiac procedure in Croatia,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,16000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Finland",22843446,Patients hospitalized for acute coronary event or cardiac procedure in Finland,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,19000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Italy",22843446,Patients hospitalized for acute coronary event or cardiac procedure in Italy,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,20000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Belgium",22843446,Patients hospitalized for acute coronary event or cardiac procedure in Belgium,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,20000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in Europe",22843446,Patients hospitalized for acute coronary event or cardiac procedure in Europe,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,20000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in France",22843446,Patients hospitalized for acute coronary event or cardiac procedure in France,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
2012-01-09556,2012,De Smedt               2012 Eur Heart J,28000,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol) VERSUS Usual care IN Patients hospitalized for acute coronary event or cardiac procedure in UK",22843446,Patients hospitalized for acute coronary event or cardiac procedure in UK,"Optimized tailored prevention for every individual (smoking cessation, diet and exercise, better management of elevated blood pressure and/or LDL-cholesterol)",Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.,Usual care,NE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
